fluorouracil has been researched along with Leucocythaemia in 80 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In the present study, we took into account the cytotoxic action of the antiviral drug acyclovir (ACV) on leukemia cells, by investigating cell cycle perturbations and apoptosis induction upon drug administration to three still unexplored cell lines, namely Jurkat, U937, and K562." | 7.88 | Acyclovir induces cell cycle perturbation and apoptosis in Jurkat leukemia cells, and enhances chemotherapeutic drug cytotoxicity. ( Battistelli, S; Benedetti, S; Canonico, B; Catalani, S; Galati, R; Luchetti, F; Palma, F; Papa, S, 2018) |
| " The conditional probability of death from breast cancer at 8 years for the entire group of women treated with epirubicin-containing regimens in all four trials was approximately 34." | 7.72 | Risk of acute leukemia following epirubicin-based adjuvant chemotherapy: a report from the National Cancer Institute of Canada Clinical Trials Group. ( Bramwell, V; Crump, M; Levine, M; Pritchard, K; Shepherd, L; Tu, D, 2003) |
| "Between 1974 and 1989, 1,474 patients with stage II or III breast cancer were treated in six prospective trials of adjuvant (n = 4) or neoadjuvant (n = 2) chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide (CTX) (FAC) with or without other drugs." | 7.69 | Treatment-related leukemia in breast cancer patients treated with fluorouracil-doxorubicin-cyclophosphamide combination adjuvant chemotherapy: the University of Texas M.D. Anderson Cancer Center experience. ( Buzdar, AU; Diamandidou, E; Frye, D; Hortobagyi, GN; Smith, TL; Witjaksono, M, 1996) |
| "The inhibitory effects of combined 5-methyltetrahydrofolate (5-CH3-THF), the physiological circulating folate species, and fluoropyrimidines, 5-fluorouracil (FUra) and 5-fluoro-2'-deoxyuridine (FdUrd), on growth of human leukemia cells, CCRF-CEM, were determined as a function of time, dose, and sequence of exposure." | 7.67 | Enhancement of fluoropyrimidine cytotoxicity by 5-methyltetrahydrofolate in a human leukemia cell line, CCRF-CEM. ( Coronnello, M; Criscuoli, L; Gualtieri, M; Mazzei, T; Mini, E; Periti, P, 1985) |
| "5-Fluorouracil (5-FU) is an antimetabolite that interferes with DNA synthesis and has been widely used as a chemotherapeutic drug in various types of cancers." | 5.56 | New uracil analog U-332 is an inhibitor of NF-κB in 5-fluorouracil-resistant human leukemia HL-60 cell line. ( Długosz-Pokorska, A; Janecka, A; Janecki, T; Kędzia, J; Pięta, M, 2020) |
| "5-fluorouracil was a relatively ineffective cytotoxic agent for exposure of short duration (4 h)." | 5.27 | Modulation of fluoropyrimidine cytotoxicity by methotrexate or 5-methyltetrahydrofolate in human leukemia cells in vitro. ( Coronnello, M; Criscuoli, L; Gualtieri, M; Mazzei, T; Mini, E; Periti, P, 1984) |
| "Two consecutive studies were undertaken in patients with advanced adenocarcinoma of the ovary to compare melphalan, adriamycin and 5-fluorouracil (MAF) with cyclophosphamide, adriamycin and 5-fluorouracil (CAF)." | 5.05 | Triple drug chemotherapy for advanced ovarian carcinoma: comparative study of two regimens. ( Aroney, RS; Dalley, DN; Levi, JA, 1981) |
| " In the present study, we took into account the cytotoxic action of the antiviral drug acyclovir (ACV) on leukemia cells, by investigating cell cycle perturbations and apoptosis induction upon drug administration to three still unexplored cell lines, namely Jurkat, U937, and K562." | 3.88 | Acyclovir induces cell cycle perturbation and apoptosis in Jurkat leukemia cells, and enhances chemotherapeutic drug cytotoxicity. ( Battistelli, S; Benedetti, S; Canonico, B; Catalani, S; Galati, R; Luchetti, F; Palma, F; Papa, S, 2018) |
| " The conditional probability of death from breast cancer at 8 years for the entire group of women treated with epirubicin-containing regimens in all four trials was approximately 34." | 3.72 | Risk of acute leukemia following epirubicin-based adjuvant chemotherapy: a report from the National Cancer Institute of Canada Clinical Trials Group. ( Bramwell, V; Crump, M; Levine, M; Pritchard, K; Shepherd, L; Tu, D, 2003) |
| "Cultured P388 (murine) and CEM (human) leukemia cells were exposed to medium including either 5-fluorouracil (5-FU) or methotorexate (MTX)." | 3.70 | Extracellular glutamine level reduction enhances 5-fluorouracil cytotoxicity. ( Sugimura, K; Sukemori, S, 1998) |
| "Between 1974 and 1989, 1,474 patients with stage II or III breast cancer were treated in six prospective trials of adjuvant (n = 4) or neoadjuvant (n = 2) chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide (CTX) (FAC) with or without other drugs." | 3.69 | Treatment-related leukemia in breast cancer patients treated with fluorouracil-doxorubicin-cyclophosphamide combination adjuvant chemotherapy: the University of Texas M.D. Anderson Cancer Center experience. ( Buzdar, AU; Diamandidou, E; Frye, D; Hortobagyi, GN; Smith, TL; Witjaksono, M, 1996) |
| "We have previously shown that pretreatment of mouse erythroleukemia (MEL) cells with the fluorinated pyrimidines 5-fluorouracil (FUra) or 5-fluorodeoxyuridine (FUdR) followed by the differentiation inducer hexamethylene bisacetamide (HMBA) greatly enhanced the magnitude of their differentiation and caused extensive cell death." | 3.68 | Enhancement of differentiation and cytotoxicity of leukemia cells by combinations of fluorinated pyrimidines and differentiation inducers: development of DNA double-strand breaks. ( Huang, Y; Scher, BM; Scher, M; Waxman, S, 1992) |
| "The inhibitory effects of combined 5-methyltetrahydrofolate (5-CH3-THF), the physiological circulating folate species, and fluoropyrimidines, 5-fluorouracil (FUra) and 5-fluoro-2'-deoxyuridine (FdUrd), on growth of human leukemia cells, CCRF-CEM, were determined as a function of time, dose, and sequence of exposure." | 3.67 | Enhancement of fluoropyrimidine cytotoxicity by 5-methyltetrahydrofolate in a human leukemia cell line, CCRF-CEM. ( Coronnello, M; Criscuoli, L; Gualtieri, M; Mazzei, T; Mini, E; Periti, P, 1985) |
| "Cultured leukemic lymphocytes originating from patients with T, B and non-T, non-B (null) leukemia were tested for their sensitivity to thymidine and 5-fluorouracil." | 3.67 | The molecular basis for the differential sensitivity of B and T lymphocytes to growth inhibition by thymidine and 5-fluorouracil. ( el-Assouli, SM, 1985) |
| "5-Fluorouracil (5-FU) is an antimetabolite that interferes with DNA synthesis and has been widely used as a chemotherapeutic drug in various types of cancers." | 1.56 | New uracil analog U-332 is an inhibitor of NF-κB in 5-fluorouracil-resistant human leukemia HL-60 cell line. ( Długosz-Pokorska, A; Janecka, A; Janecki, T; Kędzia, J; Pięta, M, 2020) |
| "Early changes in karyotype detected in breast cancer patients following ASCT are transient and do not correlate with or predict development of MDS/AML." | 1.31 | Chromosomal abnormalities in women with breast cancer after autologous stem cell transplantation are infrequent and may not predict development of therapy-related leukemia or myelodysplastic syndrome. ( Arbona, C; Benet, I; Comes, AM; García Clavel, B; García-Conde, J; Lluch, A; Martínez-Climent, JA; Marugán, I; Prósper, F; Solano, C; Vizcarra, E, 2000) |
| "5-fluorouracil was a relatively ineffective cytotoxic agent for exposure of short duration (4 h)." | 1.27 | Modulation of fluoropyrimidine cytotoxicity by methotrexate or 5-methyltetrahydrofolate in human leukemia cells in vitro. ( Coronnello, M; Criscuoli, L; Gualtieri, M; Mazzei, T; Mini, E; Periti, P, 1984) |
| "Exponentially growing cells of human cancer lines have been utilized to investigate the cytotoxic activity of antineoplastic agents." | 1.27 | The use of human cancer cell lines as a primary screening system for antineoplastic compounds. ( Baguley, BC; Finlay, GJ, 1984) |
| "Thirteen cases of acute nonlymphocytic leukemia occurred among 5455 patients, as compared to 0." | 1.26 | Acute leukemia after alkylating-agent therapy of ovarian cancer. ( Fraumeni, JF; Hoover, R; Reimer, RR; Young, RC, 1977) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 49 (61.25) | 18.7374 |
| 1990's | 8 (10.00) | 18.2507 |
| 2000's | 13 (16.25) | 29.6817 |
| 2010's | 8 (10.00) | 24.3611 |
| 2020's | 2 (2.50) | 2.80 |
| Authors | Studies |
|---|---|
| Matsuda, A | 1 |
| Takenuki, K | 1 |
| Sasaki, T | 1 |
| Ueda, T | 1 |
| Santiago-Vazquez, Y | 1 |
| Das, S | 1 |
| Das, U | 1 |
| Robles-Escajeda, E | 1 |
| Ortega, NM | 1 |
| Lema, C | 1 |
| Varela-Ramírez, A | 1 |
| Aguilera, RJ | 1 |
| Balzarini, J | 1 |
| De Clercq, E | 1 |
| Dimmock, SG | 1 |
| Gorecki, DK | 1 |
| Dimmock, JR | 1 |
| Długosz-Pokorska, A | 1 |
| Pięta, M | 1 |
| Kędzia, J | 1 |
| Janecki, T | 1 |
| Janecka, A | 1 |
| Cheng, ZY | 1 |
| Chueh, FS | 1 |
| Peng, SF | 1 |
| Lin, CH | 1 |
| Kuo, CL | 1 |
| Huang, WW | 1 |
| Chen, PY | 1 |
| Way, TD | 1 |
| Chung, JG | 1 |
| Wińska, P | 1 |
| Skierka, K | 1 |
| Łukowska-Chojnacka, E | 1 |
| Koronkiewicz, M | 1 |
| Cieśla, J | 1 |
| Bretner, M | 1 |
| Benedetti, S | 1 |
| Catalani, S | 1 |
| Palma, F | 1 |
| Canonico, B | 1 |
| Luchetti, F | 1 |
| Galati, R | 1 |
| Papa, S | 1 |
| Battistelli, S | 1 |
| Liao, YC | 1 |
| Lin, TH | 1 |
| Chen, CY | 1 |
| Lin, SB | 1 |
| Au, LC | 1 |
| Falzacappa, MV | 1 |
| Ronchini, C | 1 |
| Faretta, M | 1 |
| Iacobucci, I | 1 |
| Di Rorà, AG | 1 |
| Martinelli, G | 1 |
| Meyer, LH | 1 |
| Debatin, KM | 1 |
| Orecchioni, S | 1 |
| Bertolini, F | 1 |
| Pelicci, PG | 1 |
| Vitali, C | 1 |
| Bassani, C | 1 |
| Chiodoni, C | 1 |
| Fellini, E | 1 |
| Guarnotta, C | 1 |
| Miotti, S | 1 |
| Sangaletti, S | 1 |
| Fuligni, F | 1 |
| De Cecco, L | 1 |
| Piccaluga, PP | 1 |
| Colombo, MP | 1 |
| Tripodo, C | 1 |
| An, W | 1 |
| Nadeau, SA | 1 |
| Mohapatra, BC | 1 |
| Feng, D | 1 |
| Zutshi, N | 1 |
| Storck, MD | 1 |
| Arya, P | 1 |
| Talmadge, JE | 1 |
| Meza, JL | 1 |
| Band, V | 1 |
| Band, H | 1 |
| Zhang, Y | 1 |
| Wong, J | 1 |
| Klinger, M | 1 |
| Tran, MT | 1 |
| Shannon, KM | 1 |
| Killeen, N | 1 |
| Naito, H | 1 |
| Kidoya, H | 1 |
| Sato, Y | 1 |
| Takakura, N | 1 |
| Abe, K | 1 |
| Shimizu, R | 1 |
| Pan, X | 1 |
| Hamada, H | 1 |
| Yoshikawa, H | 1 |
| Yamamoto, M | 1 |
| Dawood, S | 1 |
| Zhang, L | 1 |
| Yang, S | 1 |
| He, YJ | 1 |
| Shao, HY | 1 |
| Wang, L | 1 |
| Chen, H | 1 |
| Gao, YJ | 1 |
| Qing, FX | 1 |
| Chen, XC | 1 |
| Zhao, LY | 1 |
| Tan, S | 1 |
| Crump, M | 1 |
| Tu, D | 1 |
| Shepherd, L | 1 |
| Levine, M | 1 |
| Bramwell, V | 1 |
| Pritchard, K | 1 |
| ROOSA, RA | 1 |
| BRADLEY, TR | 1 |
| LAW, LW | 1 |
| HERZENBERG, LA | 1 |
| CHIRIGOS, MA | 2 |
| RAUSCHER, FJ | 1 |
| KAMEL, IA | 1 |
| FANNING, GR | 1 |
| GOLDIN, A | 3 |
| HARTMANN, JR | 1 |
| ORIGENES, ML | 1 |
| MURPHY, ML | 1 |
| SITARZ, A | 1 |
| ERLANDSON, M | 1 |
| GLYNN, JP | 1 |
| MOLONEY, JB | 1 |
| HUMPHREYS, SR | 1 |
| BURCHENAL, JH | 3 |
| DOWD, JE | 1 |
| DIPAOLO, JA | 1 |
| WATNE, AL | 1 |
| FALKSON, G | 1 |
| SNYMAN, HJ | 1 |
| OBRECHT, P | 1 |
| Oelmann, E | 1 |
| Haghgu, S | 1 |
| Kulimova, E | 1 |
| Mesters, RM | 1 |
| Kienast, J | 1 |
| Herbst, H | 1 |
| Schmitmann, C | 1 |
| Kolkmeyer, A | 1 |
| Serve, H | 1 |
| Berdel, WE | 1 |
| Chen, J | 1 |
| Du, D | 1 |
| Yan, F | 1 |
| Ju, HX | 1 |
| Lian, HZ | 1 |
| Selvaraj, V | 1 |
| Alagar, M | 1 |
| Hirabayashi, Y | 1 |
| Yoon, BI | 1 |
| Tsuboi, I | 1 |
| Huo, Y | 1 |
| Kodama, Y | 1 |
| Kanno, J | 1 |
| Ott, T | 1 |
| Trosko, JE | 1 |
| Inoue, T | 1 |
| Meropol, NJ | 1 |
| Dollinger, M | 1 |
| Butterbaugh, J | 1 |
| Stoll, D | 1 |
| Giner-Sorolla, A | 1 |
| Duschinsky, R | 1 |
| Gabriel, T | 1 |
| Tautz, W | 1 |
| Nussbaum, A | 1 |
| Hoffer, M | 1 |
| Grunberg, E | 1 |
| Fox, JJ | 1 |
| Mini, E | 2 |
| Mazzei, T | 2 |
| Coronnello, M | 2 |
| Criscuoli, L | 2 |
| Gualtieri, M | 2 |
| Periti, P | 2 |
| Fritze, D | 1 |
| Dembo, AJ | 1 |
| Finlay, GJ | 1 |
| Baguley, BC | 1 |
| Schornagel, JH | 1 |
| Leyva, A | 1 |
| Pinedo, HM | 1 |
| Rizzo, SC | 1 |
| Ricevuti, G | 1 |
| Gamba, G | 1 |
| Grignani, G | 1 |
| Aroney, RS | 1 |
| Levi, JA | 1 |
| Dalley, DN | 1 |
| Zakaria, M | 1 |
| Brown, PR | 1 |
| Sack, H | 1 |
| Chandrasekaran, B | 1 |
| Kute, TE | 1 |
| Duch, DS | 1 |
| Diamandidou, E | 1 |
| Buzdar, AU | 2 |
| Smith, TL | 2 |
| Frye, D | 1 |
| Witjaksono, M | 1 |
| Hortobagyi, GN | 2 |
| Krenacs, T | 1 |
| Rosendaal, M | 1 |
| Sukemori, S | 1 |
| Sugimura, K | 1 |
| Martínez-Climent, JA | 1 |
| Comes, AM | 1 |
| Vizcarra, E | 1 |
| Benet, I | 1 |
| Arbona, C | 1 |
| Prósper, F | 1 |
| Solano, C | 1 |
| García Clavel, B | 1 |
| Marugán, I | 1 |
| Lluch, A | 1 |
| García-Conde, J | 1 |
| Ryan, DP | 1 |
| Bödding, M | 1 |
| Reimer, RR | 1 |
| Hoover, R | 1 |
| Fraumeni, JF | 1 |
| Young, RC | 1 |
| Copeland, EM | 1 |
| Dudrick, SJ | 1 |
| Waxman, S | 1 |
| Huang, Y | 1 |
| Scher, BM | 1 |
| Scher, M | 1 |
| Kalechman, Y | 1 |
| Barkai, IS | 1 |
| Albeck, M | 1 |
| Horwith, G | 1 |
| Sehagl, SN | 1 |
| Sredni, B | 1 |
| Lowenthal, RM | 1 |
| Jestrimski, KW | 1 |
| Keyomarsi, K | 1 |
| Moran, RG | 1 |
| Fernandes, DJ | 1 |
| Cranford, SK | 1 |
| Vilpo, JA | 1 |
| O'Dwyer, PJ | 1 |
| King, SA | 1 |
| Hoth, DF | 1 |
| Leyland-Jones, B | 1 |
| Herring, MK | 1 |
| Blumenschein, GR | 1 |
| el-Assouli, SM | 1 |
| Wand, H | 1 |
| Rieche, K | 1 |
| Armstrong, JG | 1 |
| Frei, E | 1 |
| Schabel, FM | 1 |
| Pruzanski, W | 1 |
| Saito, S | 1 |
| Weiss, HD | 1 |
| Walker, MD | 1 |
| Wiernik, PH | 1 |
| Hall, TC | 1 |
| Wilmanns, W | 3 |
| Hibino, S | 1 |
| Kingry, RL | 1 |
| Hobson, RW | 1 |
| Muir, RW | 1 |
| Benckhuijsen, C | 1 |
| Ravina, A | 1 |
| Shetty, PA | 1 |
| Morrone, G | 1 |
| Ota, K | 1 |
| Klein, E | 1 |
| Fennelly, JJ | 1 |
| Frick, PG | 1 |
| Schwartz, SA | 1 |
| Perry, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase 0 Trial of [F-18]-5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine[NCT01479348] | Early Phase 1 | 5 participants (Actual) | Interventional | 2011-11-01 | Terminated (stopped due to Slow, insufficient accrual.) | ||
| Phase I Trial of 5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine[NCT00359606] | Phase 1 | 58 participants (Actual) | Interventional | 1999-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Here is the number of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT01479348)
Timeframe: Date treatment consent signed to date off study, approximately 20 months and 12 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| 1/Intravenous (IV) Tetrahydrouridine (THU) | 2 |
[F-18]-5-fluoro-2'-deoxycytidine (FdCyd) was administered intravenously with administration of tetrahydrouridine (THU) and the frequency and severity of adverse events was observed. A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. Grade 0 is normal, Grade 1 is mild, Grade 2 is moderate, Grade 3 is severe or medically significant but not immediately life-threatening, Grade 4 is life-threatening consequences, and Grade 5 is death related to adverse event. (NCT01479348)
Timeframe: Within 5 days after interventions
| Intervention | adverse events (Number) | |||||
|---|---|---|---|---|---|---|
| Day 1 Adverse Events | Day 2, Grade 2 Hypoalbuminemia | Day 2, Grade 3 Anemia | Day 3 Adverse Events | Day 4 Adverse Events | Day 5 Adverse Events | |
| 1/Intravenous (IV) Tetrahydrouridine (THU) | 0 | 1 | 1 | 0 | 0 | 0 |
Radiation dosimetry was determined based on the first patients. This involved making region of interest measurements on the scan for each major organ and measuring the uptake. Using standard dosimetry software this is converted into mSv/MBq, a standard measure of dosimetry. The software is known as Organ Level INternal Dose Assessment/EXponential Modeling (OLINDA) and is commonly used to generate this kind of data. (NCT01479348)
Timeframe: 1 year
| Intervention | mSv/MBq (Mean) | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adrenals | Brain | Breasts | Gallbladder wall | Lower large intestine wall | Small intestine | Stomach wall | Upper large intestine wall | Heart wall | Kidneys | Liver | Lungs | Muscle | Ovaries | Pancreas | Red marrow | Osteogenic cells | Skin | Spleen | Testes | Thymus | Thyroid | Urinary bladder wall | Uterus | |
| 1/Intravenous (IV) Tetrahydrouridine (THU) | 1.83 | 8.17 | 1.03 | 4.05 | 2.52 | 2.13 | 1.90 | 2.04 | 1.10 | 5.26 | 6.02 | 1.82 | 1.16 | 1.57 | 1.63 | 1.14 | 1.71 | 8.65 | 1.69 | 1.03 | 1.12 | 8.23 | 7.96 | 1.63 |
Participants were scanned by positron emission tomography (PET) and lesions were measured at 4 time points after injection. (NCT01479348)
Timeframe: 9 minutes, 32 minutes, 56 minutes and 2 hours after injection
| Intervention | TBR ratio (Number) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pt 1 L. Parotid adenosquam. cell ca at 9 min | Pt 1 L. Parotid adenosquam. cell ca at 32 min | Pt 1 L. Parotid adenosquam. cell ca at 56 min | Pt 1 L. Parotid adenosquam. cell ca at 2 hrs | Pt 2 R. Parapharyngeal Spindle Cell Ca at 9 min | Pt 2 R. Parapharyngeal Spindle Cell Ca at 32 min | Pt 2 R. Parapharyngeal Spindle Cell Ca at 56 min | Pt 2 R. Parapharyngeal Spindle Cell Ca at 2 hrs | Pt 3 Non-small Cell Lung Ca at 9 min | Pt 3 Non-small Cell Lung Ca at 32 min | Pt 3 Non-small Cell Lung Ca at 56 min | Pt 3 Non-small Cell Lung Ca at 2 hrs | Pt 4 Non-small Cell Lung Ca at 9 min | Pt 4 Non-small Cell Lung Ca at 32 min | Pt 4 Non-small Cell Lung Ca at 56 min | Pt 4 Non-small Cell Lung Ca at 2 hrs | Pt 5 Hepatocellular Ca at 9 min | Pt 5 Hepatocellular Ca at 32 min | Pt 5 Hepatocellular Ca at 56 min | Pt 5 Hepatocellular Ca at 2 hrs | |
| 1/Intravenous (IV) Tetrahydrouridine (THU) | 1.4 | 1.5 | 1.5 | 1.6 | 1.9 | 1.7 | 1.7 | 1.6 | 1.4 | 1.4 | 1.5 | 1.7 | 2.4 | 2.1 | 1.6 | 2.0 | NA | NA | NA | NA |
17 reviews available for fluorouracil and Leucocythaemia
| Article | Year |
|---|---|
Radiotherapeutic management of ovarian cancer.
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Co | 1984 |
Is there a role for thymidine in cancer chemotherapy?
Topics: Cytarabine; Drug Therapy, Combination; Fluorouracil; Humans; Kinetics; Leukemia; Methotrexate; Neopl | 1982 |
High-performance liquid chromatography of nucleotides, nucleosides and bases.
Topics: Animals; Breast Neoplasms; Chromatography, High Pressure Liquid; Chromatography, Ion Exchange; Defic | 1981 |
Rectal cancer: integrating oxaliplatin into chemoradiation studies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Clinical Trials, | 2000 |
Corticosteroid drugs: their role in oncological practice.
Topics: Adrenal Cortex Hormones; Animals; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Breast | 1986 |
The DNA-repair enzyme uracil-DNA glycosylase in the human hematopoietic system.
Topics: Anemia, Megaloblastic; Bromodeoxyuridine; Cell Division; Chromosome Aberrations; DNA Glycosylases; D | 1988 |
Role of thymidine in biochemical modulation: a review.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Aspartic A | 1987 |
Neurotoxicity of commonly used antineoplastic agents (first of two parts).
Topics: Animals; Antineoplastic Agents; Asparaginase; Brain; Brain Diseases; Fluorouracil; Humans; Leukemia; | 1974 |
Predictive tests in cancer. Tuesday 9 April 1974.
Topics: Age Factors; Breast Neoplasms; Cell Movement; Clinical Enzyme Tests; Colonic Neoplasms; Cytarabine; | 1974 |
[Current status of cytostatic therapy].
Topics: Adrenal Cortex Hormones; Alkylating Agents; Antibiotics, Antineoplastic; Antineoplastic Agents; Cyta | 1974 |
Chemotherapy and the life cycle of leukaemic cells. A comparison between the growth characteristics of human acute leukaemia and the murine leukaemia L 1210.
Topics: Anilides; Animals; Cell Division; Cyclophosphamide; Cytarabine; DNA, Neoplasm; Fluorouracil; Humans; | 1969 |
[Burkitt's lymphoma and acute leukemias].
Topics: Acute Disease; Animals; Asparaginase; Burkitt Lymphoma; Child; Cyclophosphamide; Cytarabine; Dactino | 1969 |
Cancer chemotherapy today and tomorrow. (A review).
Topics: Antineoplastic Agents; Child; Fluorouracil; Forecasting; Humans; Leukemia; Mercaptopurine; Methotrex | 1971 |
[Cytostatic chemotherapy of neoplasms in children].
Topics: Adrenal Cortex Hormones; Aminopterin; Antineoplastic Agents; Asparaginase; Child; Child, Preschool; | 1971 |
[Antimetabolites].
Topics: Allopurinol; Animals; Antimetabolites; Azathioprine; Cell Division; Chemical Phenomena; Chemistry; C | 1971 |
[Competitive enzyme mechanisms in the therapy of hemoblastosis using antimetabolites].
Topics: Adult; Allopurinol; Amidohydrolases; Antimetabolites; Cytarabine; Enzyme Inhibitors; Female; Fluorou | 1968 |
Multiple combination therapy in cancer chemotherapy in Japan.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Chloroquine; Cyclophosphamide; Cytarabine; Drug | 1969 |
4 trials available for fluorouracil and Leucocythaemia
| Article | Year |
|---|---|
[Adjuvant therapy in colonic cancer].
Topics: Clinical Trials as Topic; Colonic Neoplasms; Fluorouracil; Humans; Immunotherapy; Leukemia; Prospect | 1984 |
Radiotherapeutic management of ovarian cancer.
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Co | 1984 |
Triple drug chemotherapy for advanced ovarian carcinoma: comparative study of two regimens.
Topics: Antineoplastic Agents; Bone Marrow Diseases; Carcinoma; Clinical Trials as Topic; Cyclophosphamide; | 1981 |
Remission induction in childhood leukemia with second course vincristine (NSC-67574) and prednisone (NSC-10023) therapy.
Topics: Adolescent; Antibiotics, Antineoplastic; Child; Child, Preschool; Clinical Trials as Topic; Colonic | 1970 |
60 other studies available for fluorouracil and Leucocythaemia
| Article | Year |
|---|---|
Nucleosides and nucleotides. 94. Radical deoxygenation of tert-alcohols in 1-(2-C-alkylpentofuranosyl) pyrimidines: synthesis of (2'S)-2'-deoxy-2'-C-methylcytidine, an antileukemic nucleoside.
Topics: Animals; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Screening Assays, Antitumor; Humans; I | 1991 |
Novel 3,5-bis(arylidene)-4-oxo-1-piperidinyl dimers: structure-activity relationships and potent antileukemic and antilymphoma cytotoxicity.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Dimerization; Dose-Response | 2014 |
New uracil analog U-332 is an inhibitor of NF-κB in 5-fluorouracil-resistant human leukemia HL-60 cell line.
Topics: Antimetabolites, Antineoplastic; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fluorouracil; | 2020 |
Combinational treatment of 5-fluorouracil and casticin induces apoptosis in mouse leukemia WEHI-3 cells in vitro.
Topics: Animals; Antineoplastic Agents; Apoptosis; Caspases; Cell Line, Tumor; Cell Survival; Cytochromes c; | 2020 |
Effect of Simultaneous Inhibition of Protein Kinase CK2 and Thymidylate Synthase in Leukemia and Breast Cancer Cells.
Topics: Antineoplastic Agents; Apoptosis; Benzimidazoles; Breast Neoplasms; Casein Kinase II; Cell Line, Tum | 2018 |
Acyclovir induces cell cycle perturbation and apoptosis in Jurkat leukemia cells, and enhances chemotherapeutic drug cytotoxicity.
Topics: Acyclovir; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; | 2018 |
The antileukemia activity of natural product HQ17(3) is possibly associated with downregulation of miR-17-92 cluster.
Topics: Antigens, Neoplasm; Cell Line, Tumor; DNA Topoisomerases, Type II; DNA-Binding Proteins; Fluorouraci | 2014 |
The Combination of the PARP Inhibitor Rucaparib and 5FU Is an Effective Strategy for Treating Acute Leukemias.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Survival; Disease Models | 2015 |
SOCS2 Controls Proliferation and Stemness of Hematopoietic Cells under Stress Conditions and Its Deregulation Marks Unfavorable Acute Leukemias.
Topics: Animals; Bone Marrow; Cell Differentiation; Cell Proliferation; Fluorouracil; Gene Expression Regula | 2015 |
Loss of Cbl and Cbl-b ubiquitin ligases abrogates hematopoietic stem cell quiescence and sensitizes leukemic disease to chemotherapy.
Topics: Animals; Fluorouracil; Hematopoietic Stem Cells; Humans; Leukemia; Mice; Mice, Inbred C57BL; Mice, K | 2015 |
MLL5 contributes to hematopoietic stem cell fitness and homeostasis.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Bone Marrow Transplantation; Cell Cycle; Cell D | 2009 |
Induction and expression of anti-angiogenic vasohibins in the hematopoietic stem/progenitor cell population.
Topics: Angiogenesis Inhibitors; Animals; Bone Marrow Cells; Cell Cycle Proteins; Cell Line; Cell Proliferat | 2009 |
Stem cells of GATA1-related leukemia undergo pernicious changes after 5-fluorouracil treatment.
Topics: Animals; Cell Cycle; Cell Line, Tumor; Flow Cytometry; Fluorouracil; GATA1 Transcription Factor; Leu | 2009 |
Pharmacology, pharmacogenetics, and pharmacoepidemiology: three ps of individualized therapy.
Topics: Antineoplastic Agents; Breast Neoplasms; Dose-Response Relationship, Drug; Evidence-Based Medicine; | 2009 |
Fluorouracil selectively enriches stem-like leukemic cells in a leukemic cell line.
Topics: ADP-ribosyl Cyclase 1; Antigens, CD34; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP- | 2010 |
Risk of acute leukemia following epirubicin-based adjuvant chemotherapy: a report from the National Cancer Institute of Canada Clinical Trials Group.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemot | 2003 |
Characterization of resistance to amethopterin, 8-azaguanine and several fluorinated pyrimidines in the murine lymphocytic neoplasm, P388.
Topics: Animals; Antineoplastic Agents; Azaguanine; Fluorouracil; Leukemia; Leukemia, Lymphoid; Lymphoma; Me | 1962 |
STUDIES WITH THE MURINE LEUKEMOGENIC RAUSCHER VIRUS. II. CHEMOTHERAPY OF VIRUS-INDUCED LYMPHOID LEUKEMIA.
Topics: Animals; Antineoplastic Agents; Antiviral Agents; Cyclophosphamide; Fluorouracil; Leukemia; Leukemia | 1963 |
EFFECTS OF 2'-DEOXY-5-FLUOROURIDINE (NSC-27640) AND 5-FLUOROURACIL (NSC-19893) ON CHILDHOOD LEUKEMIA.
Topics: Bone Marrow Examination; Child; Floxuridine; Fluorouracil; Leukemia; Leukopenia; Melena; Nausea; Tox | 1964 |
CHEMOTHERAPY STUDIES WITH VIRUS-INDUCED LEUKEMIA IN MICE.
Topics: Animals; Antineoplastic Agents; Cyclophosphamide; Fluorouracil; Leukemia; Leukemia, Experimental; Me | 1964 |
III. IMPROVEMENT OF CANCER CHEMOTHERAPY IN MAN.
Topics: Animals; Antineoplastic Agents; Chlorambucil; Fluorouracil; Leukemia; Leukemia, Experimental; Mercap | 1964 |
INDIVIDUALIZED CHEMOTHERAPY BY IN VITRO DRUG SELECTION.
Topics: Antineoplastic Agents; Bone Neoplasms; Dactinomycin; Female; Floxuridine; Fluorouracil; Genital Neop | 1964 |
EXPERIENCE WITH CHEMOTHERAPY OF CANCER AT THE UNIVERSITY OF PRETORIA.
Topics: Antineoplastic Agents; Aziridines; Breast Neoplasms; Cyclophosphamide; Dactinomycin; Fluorouracil; H | 1964 |
[Problems in chemotherapy illustrated by the cytostatic 5-fluoruracil and the leukemias].
Topics: Antineoplastic Agents; Cytostatic Agents; Fluorouracil; Leukemia; Uracil | 1961 |
Influence of keratinocyte growth factor on clonal growth of epithelial tumor cells, lymphoma and leukemia cells and on sensitivity of tumor cells towards 5-fluorouracil in vitro.
Topics: Cell Differentiation; Cell Division; Cell Line, Tumor; Fibroblast Growth Factor 7; Fibroblast Growth | 2004 |
Electrochemical antitumor drug sensitivity test for leukemia K562 cells at a carbon-nanotube-modified electrode.
Topics: Antineoplastic Agents; Doxorubicin; Drug Screening Assays, Antitumor; Electrochemistry; Fluorouracil | 2005 |
Analytical detection and biological assay of antileukemic drug 5-fluorouracil using gold nanoparticles as probe.
Topics: Anti-Infective Agents; Antimetabolites, Antineoplastic; Aspergillus fumigatus; Aspergillus niger; Bi | 2007 |
Protective role of connexin 32 in steady-state hematopoiesis, regeneration state, and leukemogenesis.
Topics: Animals; Bone Marrow Cells; Bone Marrow Transplantation; Cell Proliferation; Connexins; Female; Flow | 2007 |
A renewed call for equipoise.
Topics: Adenocarcinoma; Camptothecin; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; Ethi | 2007 |
Studies of 6-N-hydroxylamino-9-beta-D-ribofuranosylpurine in mouse leukemia.
Topics: Adenine; Animals; Body Weight; Cytarabine; Drug Antagonism; Drug Synergism; Fluorouracil; Guanine; L | 1967 |
Nucleosides. XXXVII. 5,6-substituted 5-fluorodihydropyrimidines and their 2'-deoxyribonucleosides.
Topics: Animals; Antineoplastic Agents; Chemical Phenomena; Chemistry; Chemistry, Organic; Chromatography, P | 1967 |
Modulation of fluoropyrimidine cytotoxicity by methotrexate or 5-methyltetrahydrofolate in human leukemia cells in vitro.
Topics: Cells, Cultured; Drug Synergism; Floxuridine; Fluorouracil; Humans; Leukemia; Methotrexate; Tetrahyd | 1984 |
The use of human cancer cell lines as a primary screening system for antineoplastic compounds.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line; Cell Survival; Colonic Neoplasms; Cytarabine; Dr | 1984 |
Multimodal treatment in operable breast cancer.
Topics: Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouracil; Humans; Leukemi | 1981 |
[Leukemia in patients with breast carcinoma after adjuvant chemotherapy and/or postoperative radiotherapy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 1995 |
Synchronization of cells in the S phase of the cell cycle by 3'-azido-3'-deoxythymidine: implications for cell cytotoxicity.
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma; Cell Division; Cell Survival; Colonic Neoplasms; | 1995 |
Treatment-related leukemia in breast cancer patients treated with fluorouracil-doxorubicin-cyclophosphamide combination adjuvant chemotherapy: the University of Texas M.D. Anderson Cancer Center experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dox | 1996 |
Connexin43 gap junctions in normal, regenerating, and cultured mouse bone marrow and in human leukemias: their possible involvement in blood formation.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aging; Animals; Blotting, Northern; Bone Marrow; Cells, | 1998 |
Extracellular glutamine level reduction enhances 5-fluorouracil cytotoxicity.
Topics: Amino Acids; Animals; Asparagine; Cell Count; Dose-Response Relationship, Drug; Fluorouracil; Glutam | 1998 |
Chromosomal abnormalities in women with breast cancer after autologous stem cell transplantation are infrequent and may not predict development of therapy-related leukemia or myelodysplastic syndrome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Breast Neoplasms; Chemotherapy, | 2000 |
Reduced store-operated Ca(2+) currents in rat basophilic leukaemia cells cultured under serum-free conditions.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Aphidicolin; Bromodeoxyuridine; Cal | 2001 |
Acute leukemia after alkylating-agent therapy of ovarian cancer.
Topics: Acute Disease; Alkylating Agents; Altretamine; Chlorambucil; Cyclophosphamide; Female; Fluorouracil; | 1977 |
Cancer: nutritional concepts.
Topics: Acute Disease; Drug Tolerance; Fistula; Fluorouracil; Humans; Leukemia; Neoplasms; Nutrition Disorde | 1975 |
Enhancement of differentiation and cytotoxicity of leukemia cells by combinations of fluorinated pyrimidines and differentiation inducers: development of DNA double-strand breaks.
Topics: Cell Differentiation; Cell Line, Transformed; Dimethyl Sulfoxide; Drug Therapy, Combination; Floxuri | 1992 |
Use and mechanism of action of AS101 in protecting bone marrow colony forming units-granulocyte-macrophage following purging with ASTA-Z 7557.
Topics: Aldehyde Dehydrogenase; Animals; Bone Marrow; Bone Marrow Purging; Colony-Forming Units Assay; Cyana | 1991 |
Enhancement of fluoropyrimidine cytotoxicity by 5-methyltetrahydrofolate in a human leukemia cell line, CCRF-CEM.
Topics: Cell Division; Cell Line; Drug Synergism; Floxuridine; Fluorouracil; Humans; Leukemia; Tetrahydrofol | 1985 |
Folinic acid augmentation of the effects of fluoropyrimidines on murine and human leukemic cells.
Topics: Animals; Cell Line; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Floxuridine; Fl | 1986 |
Resistance of CCRF-CEM cloned sublines to 5-fluorodeoxyuridine associated with enhanced phosphatase activities.
Topics: Acid Phosphatase; Alkaline Phosphatase; Biological Transport; Clone Cells; Drug Resistance; Floxurid | 1985 |
Second neoplasms after adjuvant chemotherapy for operable breast cancer.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclopho | 1986 |
The molecular basis for the differential sensitivity of B and T lymphocytes to growth inhibition by thymidine and 5-fluorouracil.
Topics: B-Lymphocytes; Cells, Cultured; Chromatography, Gel; Chromatography, Ion Exchange; Drug Resistance; | 1985 |
[The effect of cytostatic drugs on blood platelets and lymphocytes in patients with neoplasms].
Topics: Adenine Nucleotides; Adenosine Diphosphate; Amidines; Antibiotics, Antineoplastic; Bleomycin; Blood | 1974 |
Current problems in the use of the oncolytic drugs.
Topics: Antineoplastic Agents; Busulfan; Carcinoma, Squamous Cell; Child; Chlorambucil; Choriocarcinoma; Dac | 1968 |
Comparative chemotherapy of AKR lymphoma and human hematological neoplasia.
Topics: Animals; Antineoplastic Agents; Biological Assay; Carmustine; Cyclohexanes; Cyclophosphamide; Cytara | 1974 |
Influence of chemotherapeutic agents on the antibacterial activity of normal and leukemic sera.
Topics: Antineoplastic Agents; Blood Bactericidal Activity; Carmustine; Cell Membrane; Complement System Pro | 1974 |
[Clinical advances in chemotherapy of leukemia].
Topics: Adult; Antineoplastic Agents; Cytarabine; Fluorouracil; Humans; Leukemia; Male; Mitomycins | 1972 |
Cecal necrosis and perforation with systemic chemotherapy.
Topics: Adult; Asparaginase; Breast Neoplasms; Cecal Diseases; Child; Cytarabine; Daunorubicin; Female; Fluo | 1973 |
Local chemotherapy of cutaneous neoplasms.
Topics: Adenocarcinoma; Allergy and Immunology; Antineoplastic Agents; Carcinoma, Squamous Cell; Dactinomyci | 1970 |
Drugs and their abuse no. V--misuse of cytotoxic drugs.
Topics: Antineoplastic Agents; Cyclophosphamide; Fluorouracil; Humans; Leukemia; Mechlorethamine; Melphalan; | 1971 |
[Possible applications of antivitamins and antimetabolites in therapy].
Topics: Aminopterin; Antimetabolites; Azaserine; Child; Child, Preschool; Choriocarcinoma; Diazooxonorleucin | 1966 |
Patient protection in cancer chemotherapy.
Topics: Adult; Anti-Bacterial Agents; Culture Media; Cyclophosphamide; Fluorouracil; Germ-Free Life; Humans; | 1966 |